SCHEDULE: Vanguard Group Reports 0% Akebia Therapeutics Stake

The Vanguard Group reported a 0% beneficial ownership in Akebia Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Akebia Therapeutics Inc. Common Stock (CUSIP: 00972D105).
• As of March 13, 2026, The Vanguard Group reported 0 shares beneficially owned, representing 0% of the class of Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing for Akebia Therapeutics, as it primarily concerns an internal reporting realignment by The Vanguard Group rather than a change in investment thesis or a divestment of underlying holdings.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects an internal organizational change within The Vanguard Group, a common practice among large asset managers to streamline reporting or comply with specific regulatory interpretations, rather than a strategic investment decision regarding Akebia Therapeutics. This type of administrative filing is not uncommon for large, complex investment firms.

Stakeholder Impact

• Shareholders of Akebia Therapeutics: May initially perceive a large institutional holder's reported stake dropping to zero as negative, but understanding the context of Vanguard's internal realignment should mitigate concerns. The actual underlying holdings by Vanguard's subsidiaries may still exist, just reported separately.

Key Dates

Recommendation

This filing primarily details an internal reporting realignment by The Vanguard Group, resulting in their reported beneficial ownership of Akebia Therapeutics Inc. dropping to 0%. It does not reflect a change in investment thesis or a divestment by Vanguard's underlying funds, but rather a disaggregation of reporting. Therefore, it provides no new fundamental information to warrant a change in an investor's current position on Akebia Therapeutics.

Keywords

Akebia Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, SEC filing, internal realignment